Supported by Korean Society of Internal Medicine Research Fund(2012);the Seoul National University College of Medicine Research Fund(2011)
AIM: To evaluate the anti-tumor effect of clobenpropit, which is a specific H3 antagonist and H4 agonist, in combination with gemcitabine in a pancreatic cancer cell line.